Kolexia
Gouttebel Marie-Claude Oncologie médicale
Gouttebel Marie-Claude
Oncologie médicale
Hôpitaux Drôme Nord
Romans-sur-Isère, France
22 Activités
3 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs des glandes endocrines Effets secondaires indésirables des médicaments Adénocarcinome Tumeurs du pancréas Tumeurs colorectales Goutte {{person.topmesh10.name}}

Collaborateurs

Voir plus
Dramais-Marcel Dominique
Dramais-Marcel Dominique
Centre Hospitalier de Valence, Valence, France
Quintane Laurence
Quintane Laurence
Hopitaux Du Sud Manche, Avranches, France
Finot Mathilde
Finot Mathilde
Centre Hospitalier de Valence, Valence, France
Galifet Marie
Galifet Marie
Hôpitaux Drôme Nord, Romans-sur-Isère, France

Industries

Voir plus
Servier
1 collaboration(s)
Dernière en 2021
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer: Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
European journal of cancer (Oxford, England : 1990)   02 juillet 2020
Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).
2018 ASCO Annual Meeting I   01 juin 2018
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
Annals of oncology : official journal of the European Society for Medical Oncology   24 février 2016
Arobase: A phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV—A Gineco study.
2014 ASCO Annual Meeting I   20 mai 2014
{{person.lastact7.name}}
{{person.lastact7.jour}}   {{person.lastact7.date}}
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}